A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 28 → 48 locations
    • Eligibility criteria expanded, about 59 words
    • Secondary endpoints: details revised at 5 of 16 entries
  2. Trial sites expanded: 18 → 28 locationsv6
  3. Trial sites expanded: 14 → 18 locations
    • Collaborators: 3 to 1
    v5
  4. Recruitment opened
    • Trial sites expanded: 0 → 14 locations
    • Start date changed from estimate of Jun 9, 2026 to Jun 4, 2026
    v4
  5. Interventions: Doxorubicin (Drug), GSK5733584 (Drug), Paclitaxel (Drug) to Doxorubicin (Drug), Mocertatug rezetecan (Drug), Paclitaxel (Drug)v3 Show 4 more changesShow less
    • Eligibility criteria shortened, about 24 words
    • Secondary endpoints revised (16)
    • Collaborators: 2 to 3
    • Study title expanded, about 5 words
  6. Start date: Mar 5, 2026 to Jun 9, 2026
    • Primary completion date: Jan 19, 2028 to Feb 29, 2028
    • Study completion date: Mar 2, 2029 to May 30, 2029
    v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared to standard of care. The study also assesses whether Mo-Rez is safe and tolerated well by participants in comparison to standard of care and will help provide a better understanding of the main side effects of the drugs.
Trial Details
NCT Number NCT07286331
Lead Sponsor GlaxoSmithKline
Collaborators: ENGOT, GOG, APGOT
Conditions
(from sponsor)		 Neoplasms, Endometrial
Related terms Endometrial Neoplasms
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov